Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

被引：4

作者：

DeAngelo, Daniel J. ^{[1
]}

Mauro, Michael J. ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Cortes, Jorge ^{[4
]}

Rea, Delphine ^{[5
]}

Hughes, Timothy P. ^{[6
,7
]}

Minami, Hironobu ^{[8
]}

Breccia, Massimo ^{[9
]}

Talpaz, Moshe ^{[10
]}

Hochhaus, Andreas ^{[11
]}

Goh, Yeow Tee ^{[12
]}

Le Coutre, Philipp D. ^{[13
]}

Sondhi, Manu ^{[14
]}

Mishra, Kaushal ^{[14
]}

Hourcade-Potelleret, Florence ^{[15
]}

Vanasse, Gary ^{[15
]}

Aimone, Paola ^{[15
]}

Lang, Fabian ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Seoul, South Korea

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hop St Louis, Paris, France

[6] SA Pathol, Adelaide, SA, Australia

[7] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[8] Kobe Univ Hosp, Kobe, Hyogo, Japan

[9] Univ Roma La Sapienza, Rome, Italy

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Univ Klinikum Jena, Abt Hamatol Onkol, Jena, Germany

[12] Singapore Gen Hosp, Singapore, Singapore

[13] Charite Univ Med Berlin, Berlin, Germany

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Goethe Univ Frankfurt Main, Frankfurt, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

asciminib; tyrosine kinase inhibitor; clinical trial; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-102

引用

页码：S290 / S291

页数：3

共 50 条

[21] ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
Cortes, Jorge E.
Andorsky, David J.
Issa, Ghayas C.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Kim, Dennis Dong Hwan
Mayer, Jiri
Goh, Yeow-Tee
le Coutre, Philipp
Kapoor, Shruti
McCulloch, Tracey
Malek, Kamel
Yau, Lillian
Ifrah, Sophie
Larson, Richard A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S369 - S370
[22] ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Hijiya, Nobuko
Heneghan, Mallorie
Kapoor, Shruti
Dhamal, Vishal
Hoch, Matthias
Descamps, Laurence
Cardoso, Ana Paula
Pollard, Jessica
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S346 - S347
[23] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
Mauro, Michael
Hochhaus, Andreas
Hughes, Timothy
Rea, Delphine
Boquimpani, Carla
Minami, Yosuke
Apperley, Jane
Garcia-Gutierrez, Valentin
Kapoor, Shruti
Espurz, Noemi
Dhamal, Vishal
Cortes, Jorge
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
[24] ASCEMBL Phase 3 Health-Related Quality of Life (HRQL) Comparison of Asciminib and Bosutinib for Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors (TKI)
Mauro, Michael J.
Boquimpani, Carla
Rea, Delphine
Hochhaus, Andreas
Maheshwari, Vikalp Kumar
Allepuz, Alex
Patwardhan, Pallavi
Wu, Ying
DeRosa, Michael
Minami, Yosuke
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S336 - S336
[25] A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
Tomassetti, Sarah
Lee, Jennifer
Qing, Xin
CLINICAL CASE REPORTS, 2022, 10 (11):
[26] Nilotinib as frontline therapy for patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd
Nakamae, Hirohisa
Shibayama, Hirohiko
Kurokawa, Mineo
Fukuda, Tetsuya
Nakaseko, Chiaki
Kanda, Yoshinobu
Nagai, Tadashi
Ohnishi, Kazunori
Maeda, Yasuhiro
Matsuda, Akira
Amagasaki, Taro
Yanada, Masamitsu
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (05) : 624 - 632
[27] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
Atallah, Ehab L.
Sadek, Islam
Wei, David
Latremouille-Viau, Dominick
Rossi, Carmine
Damon, Andrea
Yang, Daisy
Bellefleur, Remi
Guerin, Annie
Jadhav, Kejal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
[28] Health care resource utilization in 3L+patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib
Cortes, Jorge E.
Rea, Delphine
Mauro, Michael J.
Tran, Diana
Wang, Pearl
Jadhav, Kejal
Yocolly, Aurore
Sasaki, Koji
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 915 - 923
[29] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C.
Larson, Richard A.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Dong, Dennis
Kim, Hwan
Gu, Ennan
Zhang, Yifan
Kapoor, Shruti
Agrawal, Nithya
Jinwal, Rajendra
Damon, Andrea
Sadek, Islam
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
[30] Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After.2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
Rea, Delphine
Hochhaus, Andreas
Mauro, Michael J.
Minami, Yosuke
Lomaia, Elza
Voloshin, Sergey
Turkina, Anna
Kim, Wook
Apperley, Jane F.
Cortes, Jorge E.
Abdo, Andre
Fogliatto, Laura Marie
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem
Chee, Lynette
Garcia-Gutierrez, Valentin
Sasaki, Koji
Kapoor, Shruti
Allepuz, Alex
Quenet, Sara
Bedoucha, Veronique
Boquimpani, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S295 - S296

← 1 2 3 4 5 →